Alpha 0.1.0

Biotech411

Biotechnology. Right now.

Edition of · Download edition data

Archived headlines

7 in this edition
  1. FDA forms a safety council to follow biologics after approval

    The council will oversee postmarket safety across CBER products, including cell and gene therapies and blood products.

    FDA
    Options
  2. Infilbray wins approval for neurological symptoms of type 3 Gaucher disease

    FDA cleared venglustat for adults and children weighing at least 15 kg after a study compared it with enzyme replacement therapy.

    FDA
    Options
  3. FDA clears Lembaz for infantile-onset Niemann-Pick type C

    The indication covers reducing mortality risk in patients weighing at least 7 kg whose neurological symptoms began before age six.

    FDA
    Options
  4. Rybrevant Faspro gains a head and neck cancer indication

    FDA granted accelerated approval after prior platinum chemotherapy and PD-(L)1 treatment, excluding HPV-associated oropharyngeal tumors.

    FDA
    Options
  5. FDA grants accelerated approval for Jemperli in a subset of rectal cancers

    The new indication covers adults with stage II or III locally advanced tumors that are MSI-high or mismatch-repair deficient.

    FDA
    Options
  6. Glycogen storage disease trial posts its phase 3 results

    The DTX401-CL301 registry record now includes the results tables underlying the program’s evaluation of daily cornstarch intake.

    ClinicalTrials.gov
    Options
  7. Fayuvi gains approval for pediatric Sanfilippo syndrome type A

    The indication covers neurological manifestations in children whose neurodevelopmental function is preserved.

    FDA
    Options